Need Help?

Somatic mutations called from whole-exome sequencing of PSCCE

We performed whole-exome sequencing on 46 pairs of PSCCE and matched normal sample. Somatic mutations were called using MuTect2.

Request Access

Data access policy of PSCCE study

Data Access Agreement Version 1.2.20210502 This Data Access Agreement governs the terms of access to controlled datasets generated by Department of Thoracic Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences. In signing this agreement, you agree to be bound by the terms and conditions of access set out therein. Definitions Data Provider: Department of Thoracic Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences. Data: ______________________________________(please type in the Study/Dataset/Data title and ID for the Data applied) User: An applicant, having signed this Data Access Agreement, whose User Institution has cosigned this Data Access Agreement, both of them having received acknowledgement of its acceptance. Any person listed as a co-author of the papers or publications using the Data would be considered a User and should sign this Data Access Agreement. User Institution: Institution at which the User is employed, affiliated or enrolled. A representative of it has co-signed this Data Access Agreement with the User and received acknowledgement of its acceptance. Research Participant: An individual having contributed their personal data and human genetic resource to generate the Data. Terms and Conditions In signing this Data Access Agreement: 1. The User and the User Institution accept that the Data is protected by and subject to international laws, including but not limited to Biosecurity Law of the People’s Republic of China and the People’s Republic of China Regulations on Human Genetic Resources. The Data Provider reserves the right to request and inspect data security and management documentation to ensure the adequacy of data protection measures. 2. The User and the User Institution agree to use the Data only for the advancement of medical research. And not to use the Data for the creation of products for sales or for any commercial purpose. 3. The User and the User Institution agree to preserve, at all times, the confidentiality of the information and Data. In particular, they undertake not to use, or attempt to use the Data to compromise or otherwise infringe the confidentiality of information on research participants. 4. The User and the User Institution agree to protect the confidentiality of Research Participants in any research papers or publications that they prepare by taking all reasonable care to limit the possibility of identification. 5. The User and the User Institution agree not to pursue any research with the goal to identify Research Participants and not to link or combine the Data to other information or archived data in a way that would co-identify the Research Participants, even if access to the data has been formally granted to the User and the User Institution, or is freely available without restriction. 6. The User and the User Institution agree not to transfer, distribute or disclose the Data, in whole or part, or any material derived from the Data to anyone not listed in the Data Access Agreement. 7. The User and the User Institution accept that the Data Provider bears no legal responsibility for the accuracy or comprehensiveness of the Data. 8. The User and the User Institution accept that the Data Provider accepts no liability for indirect, consequential, or incidental, damages or losses arising from use of the Data. 9. The User and the User Institution agree not to make intellectual property claims on the Data and not to use intellectual property protection in ways that would prevent or block access to any element of the Data. 10. The User and the User Institution will notify the Data Provider and the Data Access Committee as soon as they become aware of a breach of the terms and conditions of this agreement. 11. This agreement shall be effective as of the date of the last party to sign below (“Effective Date”) and shall terminate two (2) years after the Effective Date, unless terminated sooner pursuant to Section 12 below. 12. The User and the User Institution accept that this Data Access Agreement may terminate immediately upon any breach of this agreement from the User and the User Institution. Either Party may terminate this Data Access Agreement upon thirty (30) days written notice for any reason. 13. In the case of Section 11 and 12, the User and the User Institution agree to destroy any Data held, including copies and backup copies. 14. The User and the User Institution agree to destroy any Data held, once it is no longer used for approved purpose. 15. The following Sections of this Data Access Agreement shall survive its expiration or termination: Sections 1-10, Sections 13-14. 16. This Data Access Agreement shall be constructed, interpreted and governed by the laws of People’s Republic of China and shall be subject to the non-exclusive jurisdiction of the courts of People’s Republic of China. For and on behalf of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences Signature of institutional representative _______________ Print name of institutional representative _______________ Date _______________ Stamp For and on behalf of the User Print name of all User(s): _______________ _______________ _______________ _______________ _______________ _______________ Signatures of all User(s): _______________ _______________ _______________ _______________ _______________ _______________ Date _______________ For and on behalf of the User Institution Name of the User Institution _______________ Signature of institutional representative _______________ Print name of institutional representative _______________ Date _______________ Stamp

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
EGAS00001004889 Other

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Located in
EGAF00004944277 vcf 2.4 MB
EGAF00004944278 vcf 4.6 MB
EGAF00004944279 vcf 3.9 MB
EGAF00004944280 vcf 3.9 MB
EGAF00004944281 vcf 3.4 MB
EGAF00004944282 vcf 3.6 MB
EGAF00004944283 vcf 4.8 MB
EGAF00004944284 vcf 4.4 MB
EGAF00004944285 vcf 6.1 MB
EGAF00004944286 vcf 7.5 MB
EGAF00004944287 vcf 9.1 MB
EGAF00004944288 vcf 8.2 MB
EGAF00004944289 vcf 11.8 MB
EGAF00004944290 vcf 9.2 MB
EGAF00004944291 vcf 9.2 MB
EGAF00004944292 vcf 11.6 MB
EGAF00004944293 vcf 5.8 MB
EGAF00004944294 vcf 4.8 MB
EGAF00004944295 vcf 6.9 MB
EGAF00004944296 vcf 6.8 MB
EGAF00004944297 vcf 11.5 MB
EGAF00004944298 vcf 12.4 MB
EGAF00004944299 vcf 8.5 MB
EGAF00004944300 vcf 2.5 MB
EGAF00004944301 vcf 6.5 MB
EGAF00004944302 vcf 5.4 MB
EGAF00004944303 vcf 5.4 MB
EGAF00004944304 vcf 6.1 MB
EGAF00004944305 vcf 2.3 MB
EGAF00004944306 vcf 8.5 MB
EGAF00004944307 vcf 6.2 MB
EGAF00004944308 vcf 8.3 MB
EGAF00004944309 vcf 5.3 MB
EGAF00004944310 vcf 3.6 MB
EGAF00004944311 vcf 2.8 MB
EGAF00004944312 vcf 3.5 MB
EGAF00004944313 vcf 2.4 MB
EGAF00004944314 vcf 2.4 MB
EGAF00004944315 vcf 3.5 MB
EGAF00004944316 vcf 3.6 MB
EGAF00004944317 vcf 3.0 MB
EGAF00004944318 vcf 2.7 MB
EGAF00004944319 vcf 3.0 MB
EGAF00004944320 vcf 3.8 MB
EGAF00004944321 vcf 2.3 MB
EGAF00004944322 vcf 5.8 MB
46 Files (259.4 MB)